Loading...
01/11 03:08
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings report shows strong financial performance with a 41% revenue increase and a 737% net income rise. The acquisition of Gamma Innovation is expected to add significant cash flow and enhance tech capabilities. Although plasma revenue declined, pharma revenue is growing rapidly. The company's guidance indicates strong growth, and a share repurchase program is in place. However, management's refusal to provide specific future revenue targets and challenges in the plasma segment are concerns. Overall, the positive financial metrics and strategic initiatives outweigh these concerns, suggesting a positive stock price movement.
Revenue $18.6 million, up 41% year-over-year from $13.2 million in Q1 2024.
Net Income $2.59 million, a 737% increase over Q1 2024.
Adjusted EBITDA $4.9 million, a 193% increase year-over-year.
Gross Margin 62.9%, expanded over 10 points from 52.6% in Q1 2024.
Patient Affordability Revenue $8.6 million, up 261% year-over-year.
Plasma Revenue $9.4 million, down 9.2% from $10.3 million in Q1 2024.
Operating Expenses $9.2 million, up 27.8% year-over-year.
SG&A Expenses $6.7 million, increased 28.2% year-over-year.
Cash Flow Expected annual cash flow savings of $4 million to $5 million from Gamma acquisition.
Unrestricted Cash $6.9 million, with 0 debt.
New Product Acquisition: In late March, Paysign acquired Gamma Innovation, enhancing their tech stack and enabling a full front-end engagement platform integrated with core payment solutions.
New Product Features: The acquisition includes a donor engagement app, plasma-specific CRM, and donor management system, all integrated with existing payment infrastructure.
Market Expansion: Paysign's Patient Affordability business saw revenues rise 261% year-over-year to $8.6 million, with 90 active programs supporting various therapeutic areas.
Industry Engagement: The company attended the Asembia Summit 2025, hosting over 40 meetings with key decision-makers, indicating strong market engagement.
Operational Efficiency: The Gamma acquisition is expected to add $4 million to $5 million in annual cash flow through efficiency measures.
Employee Growth: The company increased its workforce to 190 employees, up from 132 year-over-year, to support business growth.
Strategic Shift: Paysign aims to expand its integrated model beyond plasma into broader pharmaceutical and healthcare sectors, focusing on patient engagement and adherence.
Plasma Business Challenges: The plasma donor compensation segment experienced a revenue decline of 9.2% due to continued source plasma supply surpluses and improved collection efficiencies at the center level, which are expected to persist throughout the year.
Competitive Pressures: The company faces competitive pressures in the plasma market, necessitating innovation and strategic acquisitions to maintain and enhance its market position.
Regulatory Issues: The company operates in a highly regulated industry, which can pose risks related to compliance and operational adjustments.
Economic Factors: Economic conditions affecting the healthcare sector may impact the demand for patient affordability solutions and plasma services.
Operational Efficiency Risks: While the Gamma acquisition is expected to yield operational efficiencies, there are inherent risks in integrating new technologies and processes.
Patient Affordability Revenue Growth: Patient affordability revenue is expected to more than double again in 2025, with Q1 revenues rising 261% year-over-year to $8.6 million.
Gamma Innovation Acquisition: The acquisition of Gamma Innovation is expected to enhance the tech stack and offer a full front-end engagement platform integrated with core payment solutions, starting with the plasma industry.
Operational Efficiency Measures: Efficiency measures from the Gamma acquisition are expected to add $4 million to $5 million in annual cash flow.
New Programs Added: 14 new programs were added in Q1, already outpacing the 10 new programs added in the same period last year.
2025 Revenue Guidance: Total revenues are expected to be in the range of $72 million to $74 million, reflecting year-over-year growth of 25% at the midpoint.
Plasma Revenue Decline: Plasma revenue is estimated to decline by 8% to 10% year-over-year, making up approximately 57% of total revenue.
Pharma Revenue Growth: Pharma revenue is expected to grow over 135% year-over-year, making up approximately 43% of total revenue.
Net Income Projection: Net income is projected to be between $6 million and $7 million for the year, or $0.10 to $0.12 per fully diluted share.
Adjusted EBITDA Projection: Adjusted EBITDA is expected to be in the range of $16 million to $17 million, or $0.28 to $0.30 per fully diluted share.
Q2 2025 Revenue Guidance: Total revenue for Q2 2025 is expected to be in the range of $18.5 million to $19 million.
Share Repurchase: Repurchased 100,000 shares of stock for approximately $376,000.
The earnings call indicates strong growth prospects, with significant year-over-year improvements in financial metrics, increased revenue guidance, and operational efficiencies. The Q&A section supports optimism with plans for new programs and systems, despite management's lack of specific details. The raised revenue guidance and anticipated FDA approval for new systems suggest positive momentum. However, the lack of clear guidance on some metrics and confidentiality constraints slightly temper the outlook, preventing a 'Strong positive' rating.
The company's earnings call indicates strong financial performance, with significant revenue growth and improved margins driven by the patient affordability business. Despite some decline in plasma revenue, the overall outlook is optimistic with a promising pipeline of new programs and operational efficiencies. The Q&A section suggests positive sentiment from analysts, with inquiries focused on growth and expansion. The strategic acquisition and efficient operations further enhance prospects, leading to a positive stock price prediction.
The earnings report shows strong financial performance with a 41% revenue increase and a 737% net income rise. The acquisition of Gamma Innovation is expected to add significant cash flow and enhance tech capabilities. Although plasma revenue declined, pharma revenue is growing rapidly. The company's guidance indicates strong growth, and a share repurchase program is in place. However, management's refusal to provide specific future revenue targets and challenges in the plasma segment are concerns. Overall, the positive financial metrics and strategic initiatives outweigh these concerns, suggesting a positive stock price movement.
The earnings call presents mixed signals. While the company reports strong year-over-year revenue and EBITDA growth, challenges in the plasma business and operational costs pose risks. The Q&A reveals uncertainty in future revenue from new programs and the Gamma acquisition. The share repurchase program offers some positive sentiment, but concerns about regulatory pressures and economic factors balance the outlook. The lack of clear guidance on new programs and potential plasma business pressures contribute to a neutral sentiment.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
